China Cancer Drug Misuse In Spotlight After Shocking Whistleblower Tales
Guideline Non-Compliance, Off-Label Use
Executive Summary
Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.
You may also be interested in...
Anti-Tumor Drugs Under Closer Scrutiny As China Confronts Widespread Misuse
China has introduced new rules relating to the designation and control of cancer drugs, which are being seen by some specialists as not ideal from a clinical practice perspective but positive for novel drug development.
China’s First CAR-T Is From Fosun Kite; Overseas Data Played Key Role
Confounding earlier speculation, the Fosun-Kite joint venture rather than Juno-WuXi AppTec, gains the first CAR-T cell therapy approval in China. The clearance is expected to be followed by several others in the highly active area.
Fosun Kite Bags First China CAR-T Green Light
Confounding earlier speculation, the first CAR-T cell therapy to gain approval in China is from the Fosun-Kite joint venture rather than Juno-WuXi AppTec. But pricing and market competition challenges are just beginning.